 Now Id like to turn the call over to Mike Rice, President and CEO of BioLife. For the last month or so of the quarter, we had our team members either working from home, part of an essential reduced on site workforce who are not working through all the transition to get our customer support teams up and running remotely, we stayed in close contact with our customers and shipped more media products than in any other period and BioLife history. While its clear that cell and gene therapy clinical trials have been significantly affected by the reallocation of hospital beds to COVID patients, our customers are planning for success and clearly demonstrated through their order volume that our media products are considered mission critical to their cell and gene therapy manufacturing workflow. 